Viking Therapeutics to Present at Key Biotech Conferences Amid Phase 3 Trials

Event summary

  • Viking Therapeutics will participate in 1-on-1 meetings at the Raymond James Biotech/BioPharma Conference on April 14, 2026, in New York.
  • The company will also attend the Piper Sandler Spring Biopharma Symposium on April 16, 2026, in Boston.
  • Viking is advancing VK2735 in Phase 3 obesity trials (VANQUISH-1 and VANQUISH-2) with positive Phase 1 and Phase 2 data.
  • VK2809 met primary and secondary endpoints in a Phase 2b NASH trial and showed significant LDL-C reductions in a Phase 2a NAFLD study.

The big picture

Viking Therapeutics is positioning itself as a key player in metabolic and endocrine disorder treatments, with multiple clinical-stage assets. The company’s participation in high-profile investor conferences comes at a critical juncture as it advances its lead candidates through pivotal trials. Success in these programs could solidify its market presence, while investor interest will be crucial for securing the necessary funding to sustain its pipeline.

What we're watching

Clinical Milestones
The pace at which Viking Therapeutics advances VK2735 and VK2809 through Phase 3 trials will determine its competitive positioning in metabolic and endocrine disorder treatments.
Investor Sentiment
How investor feedback from these conferences impacts Viking’s valuation and access to capital for further development.
Regulatory Pathways
Whether the positive Phase 2 data for VK2809 translates into smooth regulatory approval processes for NASH and NAFLD indications.